Immunotherapies to prevent mother-to-child transmission of HIV

Current HIV Research

Volumn 11, Issue 2, 2013, Pages 137-143

  Hicar, Mark D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibodies; HIV; Immunoglobulin; Immunotherapy; Maternal to child transmission; Neutralizing; Pediatric; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYPERIMMUNE GLOBULIN; INTERLEUKIN 2; LIVE VACCINE; MN GP 120; NEVIRAPINE; PLACEBO; SF 2 GP 120; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; REVIEW; SINGLE DRUG DOSE; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; BREAST FEEDING; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 84875840151     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X11311020006     Document Type: Review

References (60)

1. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: pathogenesis, mechanisms and pathways. Clin Perinatol 2010; 37(4): 721-37, vii.
2. Mofenson LM. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2010; 50 Suppl 3: S130-48.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med 1994; 331(18): 1173-80.
4. McGowan JP, Shah SS. Prevention of perinatal HIV transmission during pregnancy. J Antimicrob Chemother 2000; 46(5): 657-68.
5. Mepham SO, Bland RM, Newell ML. Prevention of mother-tochild transmission of HIV in resource-rich and-poor settings. BJOG 2011; 118(2): 202-18.
6. Cunningham CK, McFarland E. Vaccines for prevention of motherto-child transmission of HIV. Curr Opin HIV AIDS 2008; 3(2): 151-4.
7. Luzuriaga K, Sullivan JL. Prevention of mother-to-child transmission of HIV infection. Clin Infect Dis 2005; 40(3): 466-7.
8. Aldrovandi GM, Kuhn L. What infants and breasts can teach us about natural protection from HIV infection. J Infect Dis 2010; 202 Suppl 3: S366-70.
9. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5(5): 428-34.
10. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71.
11. Brown-Peterside P, Ren L, Hirsch A, Drucker M, Koblin BA. Pregnancies among high-risk women in the first ever HIV vaccine efficacy trial. AIDS 2003; 17(5): 787-8.
12. Keefer MC, Wolff M, Gorse GJ, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997; 13(14): 1163-77.
13. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccineinduced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372(9653): 1894-905.
14. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
15. Fitzgerald DW, Janes H, Robertson M, et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 2011; 203(6): 765-72.
16. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
17. Gilbert PB, Berger JO, Stablein D, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203(7): 969-75.
18. Lee D, Graham BS, Chiu YL, et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004; 190(5): 903-7.
19. Van Rompay KK, Abel K, Lawson JR, et al. Attenuated poxvirusbased simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38(2): 124-34.
20. Lambert JS. HIV vaccines in infants and children. Paediatr Drugs 2005; 7(5): 267-76.
21. Wright PF, Lambert JS, Gorse GJ, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virusinfected pregnant women. J Infect Dis 1999; 180(4): 1080-8.
22. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179(3): 567-75.
23. Onyango-Makumbi C, Omer SB, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011; 58(4): 399-407.
24. Lambert JS, McNamara J, Katz SL, et al. Safety and immunogenicity of HIV recombinant envelope vaccines in HIVinfected infants and children. National Institutes of Healthsponsored Pediatric AIDS Clinical Trials Group (ACTG-218). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19(5): 451-61.
25. Cunningham CK, Wara DW, Kang M, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis 2001; 32(5): 801-7.
26. Borkowsky W, Wara D, Fenton T, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 2000; 181(3): 890-6.
27. Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 2005; 192(12): 2129-33.
28. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006; 20(11): 1481-9.
29. Lohman-Payne B, Slyker J, Rowland-Jones SL. Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization. Clin Perinatol 2010; 37(4): 787-805, ix.
30. de Vries BS, Peek MJ. Exploring the mechanisms of intrapartum transmission of HIV. Does elective caesarean section hold the key? BJOG 2008; 115(6): 677-80.
31. Schramm DB, Meddows-Taylor S, Gray GE, Kuhn L, Tiemessen CT. Low maternal viral loads and reduced granulocyte-macrophage colony-stimulating factor levels characterize exposed, uninfected infants who develop protective human immunodeficiency virus type 1-specific responses. Clin Vaccine Immunol 2007; 14(4): 348-54.
32. Legrand FA, Nixon DF, Loo CP, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One 2006; 1: e102.
33. Abramczuk BM, Mazzola TN, Moreno YM, et al. Impaired Humoral Response to Vaccines Among HIV-Exposed Uninfected Infants. Clin Vaccine Immunol 2011; 18(9): 1406-9.
34. Mascola JR, Lewis MG, VanCott TC, et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol 2003; 77(19): 10348-56.
35. Samleerat T, Thenin S, Jourdain G, et al. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology 2009; 387(2): 388-94.
36. Barin F, Jourdain G, Brunet S, et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J Infect Dis 2006; 193(11): 1504-11.
37. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6(2): 207-10.
38. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA 2005; 102(51): 18514-9.
39. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100(7): 4144-9.
40. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80(19): 9586-98.
41. Kliks SC, Wara DW, Landers DV, Levy JA. Features of HIV-1 that could influence maternal-child transmission. JAMA 1994; 272(6): 467-74.
42. Dickover RE, Garratty EM, Plaeger S, Bryson YJ. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001; 75(5): 2194-203.
43. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464(7286): 217-23.
44. Cicala C, Arthos J, Fauci AS. HIV-1 envelope, integrins and coreceptor use in mucosal transmission of HIV. J Transl Med 2011; 9 Suppl 1: S2.
45. Heath L, Conway S, Jones L, et al. Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmission. PLoS One 2010; 5(4): e10213.
46. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177(6): 4028-36.
47. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6(2): 200-6.
48. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5(5): e1000433.
49. Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010; 16(10): 1117-9.
50. Murakami T, Eda Y, Nakasone T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS 2009; 23(12): 1485-94.
51. Joag SV, Li Z, Wang C, et al. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus. AIDS Res Hum Retroviruses 1999; 15(4): 391-4.
52. Fouda GG, Yates NL, Pollara J, et al. HIV-Specific Functional Antibody Responses in Breast Milk Mirror Those in Plasma and Are Primarily Mediated by IgG Antibodies. J Virol 2011; 85(18): 9555-67.
53. Tudor D, Derrien M, Diomede L, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgGseronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2(5): 412-26.
54. Mestecky J, Wright PF, Lopalco L, et al. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 2011; 27(5): 469-86.
55. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449(7158): 101-4.
56. Blish CA, Dogan OC, Derby NR, et al. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 2008; 82(24): 12094-103.
57. Lynch JB, Nduati R, Blish CA, et al. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol 2011; 85(11): 5252-61.
58. Banhegyi D, Bacsi A, Toth FD, et al. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol Lett 2003; 89(1): 25-30.
59. Mofenson LM. Prevention of mother-to-child HIV-1 transmission--why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr 2011; 58(4): 359-62.
60. Safrit JT, Ruprecht R, Ferrantelli F, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35(2): 169-77.